Claire Mazumdar, the niece of Kiran Mazumdar, launched the biotech company Bicara Therapeutics, which has raised $108 million in a Series B fundraising round. F-Prime Capital, Eight Roads Ventures, Invus, Piper Heartland Healthcare Capital, and Premji Invest also participated in the round, which was jointly led by Red Tree Venture Capital and RA Capital Management. Omega Funds, Bioqube Ventures, Acorn Bioventures, and Janus Henderson Investors are some recent investors.

In conjunction with the financing, Krishna Polu, M.D., Principal at Red Tree Venture Capital, Jake Simson, Ph.D., Partner at RA Capital Management, and Ketan Patel, M.D., Partner at F-Prime Capital, will join Bicara’s Board of Directors.

Cambridge-based Bicara, a spinout of India biotech Biocon Ltd., is behind a suite of cancer drugs that combine targeted therapies and immunotherapies into a single, precision antibody. The company intends to use the funds to support future studies of lead program BCA101, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth.

Led by CEO Claire Mazumdar, Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the targeted therapy and tumor modulators. Its bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Its lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study.